AI Article Synopsis
- The study focused on patients with locally advanced pancreatic adenocarcinoma (PDAC) who were treated with induction FOLFIRINOX to improve surgical outcomes and survival rates.
- It reviewed the cases of 200 patients, where 70% received radiation therapy and about 18% were able to undergo surgery after treatment.
- Findings showed that resected patients had a median overall survival of 36 months, while patients who remained unresectable but stable had a median survival of about 24 months, highlighting the potential for further treatment optimization in unresectable cases.
Article Abstract
Objectives: Patients with locally advanced pancreatic adenocarcinoma (PDAC) receive induction chemotherapy with or without radiation, with the goal of R0 resection and improving survival. Herein, we evaluate the outcomes of patients who presented with Stage III PDAC and received induction FOLFIRINOX.
Methods: An institutional database was queried for consecutive patients who received induction FOLFIRINOX for locally unresectable PDAC between 2010 and 2016. Clinical and radiographic parameters were assessed pre- and posttreatment, and clinical outcomes were evaluated.
Results: There were 200 patients who met the inclusion criteria. The median number of cycles of FOLFIRINOX was 8, 70% (n = 140) received radiation, and 18% (n = 36) underwent resection. Median overall survival (OS) in resected patients was 36 months (95% confidence interval [CI]: 24-56), and this group had improved OS compared to patients that did not undergo resection (hazard ratio (95% CI): 0.41 (0.26-0.64), p < 0.001). Patients (n = 112) who did not progress on induction therapy but remained unresectable had a median OS of 23.9 months (95% CI: 21.1-25.4).
Conclusion: Nearly 20% of patients with locally advanced PDAC responded sufficiently to induction FOLFIRINOX to undergo resection, which was associated with improved OS compared to patients that did not undergo resection. Patients with stable disease who remain unresectable represent a group of patients with locally advanced PDAC who may benefit from optimization of additional nonoperative treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933849 | PMC |
| http://dx.doi.org/10.1002/jso.26735 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study.
Clin Res Hepatol Gastroenterol
January 2025
Sorbonne University, Hepato-gastroenterology and digestive oncology department, Pitié Salpêtrière hospital, APHP, Paris, 47-83 Boulevard de l'hôpital, Paris 75013, France. Electronic address:
Aim Of The Study: The management of synchronous metastatic rectal cancer (SMRC) is complex and multimodal, involving chemotherapy, surgery and/or radiotherapy. The aim of this study was firstly to confirm the efficacy of the induction FOLFIRINOX, and secondly to evaluate the different therapeutic strategies and outcomes of patients.
Patients And Methods: This French study combined data from a prospective FFCD trial and a multicenter cohort.
Distal Pancreatectomy with Celiac Axis and Venous Resection with Hepatic Artery and Venous Reconstruction (DP-CARV) for Locally Advanced Pancreatic Adenocarcinoma.
Ann Surg Oncol
December 2024
Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Pôle des Pathologies Hépatiques et Digestives, Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France.
Background: Surgery has recently been introduced into the multimodal management of patients with locally advanced pancreatic adenocarcinomas (LAPCs) thanks to the major pathological response seen with the advent of the multiagent regimen FOLFIRINOX. Distal pancreatectomy with celiac axis resection (DP-CAR) may be complicated by ischemic liver and gastric events. Common hepatic artery reconstruction may prevent the occurrence of ischemic complications and can be an alternative to preoperative embolization of the celiac trunk.
View Article and Find Full Text PDFStereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Clinical CA209-9KH Trial.
Oncol Ther
December 2024
Department of Oncology and Radiotherapy, University Hospital Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic.
Article Synopsis
- The study aims to explore the safety and efficacy of combining stereotactic radiotherapy (SRT) with the immune checkpoint inhibitor nivolumab in patients with unresectable pancreatic ductal adenocarcinoma (PDAC).
- Out of 22 screened patients, 15 participated, experiencing manageable side effects and demonstrating that SRT had low toxicity while nivolumab showed no severe adverse events.
- Findings revealed median progression-free survival (8.1 months) and overall survival (13.0 months) rates, but long-term effectiveness was not achieved, indicating a need for alternative approaches to enhance antitumor immunity in PDAC.
Induction treatment with FOLFIRINOX or oxaliplatin-based doublet followed by long-course chemoradiotherapy and surgery in locally advanced rectal cancer. A systematic review and pooled analysis from phase II and III trials.
Cancer Treat Rev
November 2024
Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. Electronic address:
Article Synopsis
- The PRODIGE-23 study indicates that FOLFIRINOX is more effective than neoadjuvant chemoradiotherapy alone in improving disease-free and overall survival for locally advanced rectal cancer.
- This research aims to evaluate survival rates, rates of pathological complete response, and safety of triplet versus doublet induction chemotherapy before further treatment.
- A systematic review of clinical trials was conducted to analyze data, focusing on comparison outcomes like disease-free survival and overall survival rates between different chemotherapy induction methods.
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.
Oncologist
September 2024
Department of Gastroenterology, University Hospital Pontchaillou, Rennes 1 University, INSERM U1242 "Chemistry Oncogenesis Stress Signalling," Rennes, France.
Article Synopsis
- The study investigates predictive markers for the benefits of LV5FU2 maintenance therapy after first-line FOLFIRINOX treatment in patients with metastatic pancreatic cancer.
- It compares two patient groups from the PRODIGE-35 trial: one receiving 12 cycles of FOLFIRINOX, and another receiving 8 cycles followed by LV5FU2 maintenance.
- Results indicate that certain factors, like age and metastatic sites, affect patient outcomes, suggesting that LV5FU2 maintenance is generally beneficial except for some specific cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!